A systematic review including 43 studies with a total of 11 281 subjects was abstracted in DARE.
The absolute, weighted average reductions in diastolic (8.2 to 8.9 mmHg) and systolic (10.4 to 11.8 mmHg) blood-pressure (not placebo-corrected) for AIIA monotherapy were comparable for all AIIAs. Rates of patients responding to AIIA monotherapy were 48 to 55%. Dose titration resulted in slightly greater blood-pressure reduction and an increase in responder rates to 53 to 63%.
AIIA-HCTZ combinations produced substantially greater reductions in systolic (16.1 to 20.6 mmHg) and diastolic (9.9 to 13.6 mmHg) blood-pressure than AIIA monotherapy, and responder rates were 56 to 70%.